InvestorsHub Logo

Whalatane

02/16/24 6:52 PM

#17332 RE: rosemountbomber #17331

I think Leerink published a note along the lines of Z's opinion .
There are however several biotech Co's interested in LN ...


” Brad H. Rovin, MD, co-chair of the guideline review, said in a press release. “With ongoing trials evaluating additional novel therapeutics and promising new data on the horizon, the guideline sets the stage for future advancements in the management and treatment of LN.”



Good luck
Kiwi